The PanTracer portfolio reflects our commitment to evolving with the needs of oncology care—offering tests that are practical, powerful, and designed to support real-world clinical decisions.
Powerful, simple solutions for therapy selection
- A solution offering a holistic genomic picture and a frictionless, single-source workflow
- Guideline-driven tests
- Rapid turnaround time
- Advanced HRD assessment available to support ovarian cancer patients
Liquid and tissue comprehensive genomic profiling (CGP) testing solutions for patients with advanced-stage solid tumors
PanTracer Tissue, PanTracer Tissue + HRD and PanTracer LBx
Next-generation diagnostic solutions for patients with advanced-stage solid tumors.
The PanTracer portfolio empowers oncologists with actionable genomic insights for confident, real-time treatment decisions. Whether you’re selecting approved targeted therapies or exploring clinical trials, working from a liquid or tissue biopsy, PanTracer ensures that you’re equipped with the insights you need.
PanTracer Tissue, the next evolution of Neo Comprehensive - Solid Tumor, offers a tissue-based CGP approach, providing deep insights into tumor genomics from solid-tumor biopsy samples, helping oncologists make precise, actionable therapy decisions.
PanTracer Tissue + HRD is a single, advanced assay designed specifically for advanced ovarian cancer, uniquely combining Comprehensive Genomic Profiling (CGP) and HRD assessment in one streamlined solution.
PanTracer LBx delivers comprehensive, clinically actionable insights from a simple blood draw to support real-time decision making, especially for patients for whom tissue biopsies are not feasible.
PanTracer video
PanTracer portfolio features
 | Broad, guideline-compliant CGP panels |
| Rapid turnaround time |
| Actionable and informative reports |
| Minimal specimen requirements |